Zelira has entered into an exclusive licensing agreement with Alternative Solutions for its Hope autism products in the Washington DC Approved Medical Cannabis Market.
Under the terms of the licensing agreement, Zelira will receive an upfront fee and ongoing royalties from Hope product sales in Washington DC, while Alternative Solutions will handle the manufacturing and distribution in that state.
Washington DC has reciprocity with 32 other states in the US with approved medical cannabis programs. This expands access to patients registered in all 32 states as they can legally purchase medical cannabis products at an approved dispensary in Washington DC.
Zelira has previously licensed Hope in Pennsylvania to Ilera Healthcare LLC, which holds the licence for that state, and in Louisiana to Advanced Biomedics LLC. Zelira remains focused on expanding the distribution of Hope through licensing agreements in each approved market across the US next year.
Zelira CEO and managing director USA Dr Oludare Odumosu said: “Our partnership with Alternative Solution, a leader in the Washington DC market, is a strategic move in line with our mission of working with market leaders in approved markets to expand access to Hope across the US.
“We are particularly excited about this partnership because Washington DC is a gateway state with over 24 million visitors passing though the US capital in a year. Washington DC’s reciprocity is a strategic move that allows approved patients from 32 states to legally access Hope in DC.”
CEO for Alternative Solutions Matt Lawson-Baker said: “Alternative Solutions is thrilled to be partnering with Zelira to bring the Hope product line to the Washington DC medical cannabis market. Providing access to this medicine in the nation’s capital will give many families and patients the treatment they deserve through a legal, regulated medical cannabis program.”
